HDAC9 and primary cutaneous T-cell non-Hodgkin lymphoma: Vorinostat [6] and Romidepsin [7] are two HDAC inhibitors recently approved by the U.S. Food and Drug Administration (FDA) for cutaneous T-cell lymphoma (CTCL).